Because everyone deserves to be comfortable in their own skin.
Quoin Pharmaceuticals launched NETHERTON NOW, a campaign dedicated to raising awareness, fostering advocacy, and supporting patients and families affected by Netherton Syndrome.
Dedicated to bringing hope to underserved patients.
We are relentlessly focused on developing therapeutic products to address a range of rare diseases and we are humbled and inspired every day by the courage of patients, their families and their care teams.
Our Motivation
Patients are at the center of everything we do. To ensure our rare disease products reach every patient who needs them, no matter where they are in the world, we have established exclusive international marketing and distribution partnerships covering 61 countries to augment our own planned commercial infrastructure for the US, Western Europe and Japan.
Focused on hope through comprehensive clinical trials.
Quoin Pharmaceuticals is conducting multiple ongoing clinical studies, including two pivotal studies, to evaluate QRX003 for the treatment of Netherton Syndrome under an open U.S. Investigational New Drug (IND).
Rare diseases are only rare if you don’t live with one.®
Subscribe to Email Alerts
Sign up for alerts to stay up to date on Quoin Pharmaceuticals.
Latest News:
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic...
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome –...